- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05174585
JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
March 20, 2024 updated by: Jacobio Pharmaceuticals Co., Ltd.
A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
This study is to evaluate the safety and tolerability of JAB-BX102 monotherapy and combination therapy with pembrolizumab in adult participants with advanced solid tumors.
Study Overview
Status
Recruiting
Conditions
Detailed Description
The primary objective of this study is to evaluate the safety and tolerability of JAB-BX102 monotherapy to determine the MTD(maximum tolerated dose) and RP2D(Recommended Phase 2 Dose) during Dose Escalation phase; then to evaluate preliminary antitumor activity when JAB-BX102 is administered in combination with pembrolizumab during Dose Expansion phase in patients with advanced solid tumors.
Study Type
Interventional
Enrollment (Estimated)
62
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jacobio Pharmaceuticals
- Phone Number: (781) 918-6670
- Email: clinicaltrials@jacobiopharma.com
Study Contact Backup
- Name: Zhiwen He
- Email: Zhiwen.he@jacobiopharma.com
Study Locations
-
-
Anhui
-
Bengbu, Anhui, China, 233004
- Recruiting
- The First affiliated hospital of bengbu medical college
-
-
Beijing
-
Beijing, Beijing, China, 100191
- Recruiting
- Peking University Third Hospital
-
Beijing, Beijing, China, 100021
- Recruiting
- Cancer Hospital Chinese Academy of Medical Sciences
-
-
Henan
-
Zhengzhou, Henan, China, 450052
- Not yet recruiting
- The First Affiliated Hospital of Zhengzhou University
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Not yet recruiting
- Hunan Cancer Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China, 200040
- Recruiting
- Huashan Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Must be able to provide an archived tumor sample
- Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor
- Must be refractory to or become intolerant of existing therapy(ies) known to provide clinical benefit for their condition, or patient has no access to SOC treatment.
- Must have at least 1 measurable lesion per RECIST v1.1
- Must have adequate organ functions
Exclusion Criteria:
- Has central nervous system(CNS) metastases or carcinomatous meningitis, except if CNS metastases treated and no evidence of radiographic progression or hemorrhage for at least 28 days
- Active infection requiring systemic treatment within 7 days
- Active hepatitis C virus(HBV), hepatitis C virus(HCV), or HIV
- Any severe and/or uncontrolled medical conditions
- Left ventricular ejection fraction(LVEF) ≤50% assessed by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
- QTcF(Corrected QT interval - Fredericia formula) interval >470 msec
- Experiencing unresolved CTCAE 5.0 Grade >1 toxicities
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A, JAB-BX102 monotherapy, Phase 1, Dose Escalation
Dose escalation of JAB-BX102 will be administered as monotherapy to determine the MTD and RP2D.
|
Administered by intravenous infusion (IV)
|
Experimental: Arm B, JAB-BX102 combination with pembrolizumab, Phase 2a, Dose Expansion
JAB-BX102 will be administered in combination with pembrolizumab in specific solid tumor patients to evaluate the preliminary antitumor activity.
|
Administered by intravenous infusion (IV)
Administered by intravenous infusion (IV)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Escalation phase Number of participants with dose limiting toxicities (DLTs)
Time Frame: First 21 days of Cycle 1
|
A DLT is defined as the clinically significant TRAE(treatment-related adverse events) or abnormal laboratory values assessment during the first 21 days of Cycle 1 and excludes events that are deemed clearly related to underlying disease, progression, or intercurrent illness.
|
First 21 days of Cycle 1
|
Dose Escalation and Dose Expansion phase: Number of participants with adverse events
Time Frame: Up to 3 years
|
Patients will be assessed for incidence and severity of adverse events (AEs) according to NCI-CTCAE 5.0.
|
Up to 3 years
|
Dose Expansion phase: Overall response rate (ORR)
Time Frame: Up to 3 years - from baseline to RECIST confirmed Progressive Disease
|
ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) per RECIST v 1.1.
|
Up to 3 years - from baseline to RECIST confirmed Progressive Disease
|
Expansion phase: Duration of response (DOR)
Time Frame: Up to 3 years
|
DOR is defined as the time from the participant's initial objective response (CR or PR) to disease progression per CTCAE v1.1 or death due to any cause, whichever occurs first.
|
Up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Escalation phase: Overall response rate (ORR)
Time Frame: Up to 3 years - from baseline to RECIST confirmed Progressive Disease
|
The percentage of participants with complete response (CR) or partial response (PR) on RECIST v 1.1.
|
Up to 3 years - from baseline to RECIST confirmed Progressive Disease
|
Dose Escalation phase: Duration of response (DOR)
Time Frame: Up to 3 years
|
DOR is defined as the time from the participant's initial objective response (CR or PR) to disease progression per CTCAE v1.1 or death due to any cause, whichever occurs first.
|
Up to 3 years
|
Dose Escalation and Dose Expansion phase: Disease Control Rate (DCR)
Time Frame: Up to 3 years
|
DCR is defined as percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) per CTCAE v1.1.
|
Up to 3 years
|
Dose Escalation and Dose Expansion phase: Progression-free survival (PFS)
Time Frame: Up to 3 years
|
PFS is defined as the interval of time between the date of first treatment to the earliest date of disease progression per CTCAE v1.1 or death which occurs first
|
Up to 3 years
|
To characterize the pharmacokinetics(PK) profile of JAB-BX102 as a single agent and in combination with pembrolizumab
Time Frame: Up to 3 years
|
observed plasma concentration of JAB-BX102
|
Up to 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 18, 2022
Primary Completion (Estimated)
March 1, 2024
Study Completion (Estimated)
March 1, 2026
Study Registration Dates
First Submitted
December 14, 2021
First Submitted That Met QC Criteria
December 14, 2021
First Posted (Actual)
January 3, 2022
Study Record Updates
Last Update Posted (Actual)
March 22, 2024
Last Update Submitted That Met QC Criteria
March 20, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- JAB-BX102-1001
- MK-3475-E58 (Other Identifier: Merck Sharp & Dohme LLC)
- KEYNOTE-E58 (Other Identifier: Merck Sharp & Dohme LLC)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
Clinical Trials on JAB-BX102 (anti-CD73 monoclonal antibody)
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Osteosarcoma | Refractory Osteosarcoma | Metastatic Osteosarcoma | Metastatic Angiosarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Recurrent Angiosarcoma | Refractory Dedifferentiated LiposarcomaUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingRecurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditionsUnited States, Puerto Rico
-
Biotech Pharmaceutical Co., Ltd.Terminated
-
Bio-Thera SolutionsActive, not recruitingAdvanced Solid TumorsChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2 Positive Breast CarcinomaUnited States
-
Shanghai Henlius BiotechNot yet recruiting
-
Henlix, IncTerminated
-
Shanghai Henlius BiotechCompleted
-
National Institute of Dental and Craniofacial Research...Terminated
-
HuniLife Biotechnology, Inc.RecruitingIdiopathic Pulmonary FibrosisTaiwan